Sareum’s strategy is to develop programmes to late preclinical or early clinical stages before licensing or partnering.
Sareum is a clinical stage small molecule drug development company which is focused on advancing molecules in the JAK kinase family into clinical development for autoimmune disease and cancer. It is led by a highly experienced team with expertise in kinase inhibition and decades of experience in R&D and public company management.
Sareum’s pipeline is focused on the TYK/JAK signalling family, which is critical for maintaining a healthy immune system. The JAK kinase family is an area of growing scientific and commercial focus, with strong clinical validation in psoriasis and psoriatic arthritis.
Our approach is to discover and develop programmes to late preclinical or early clinical stages before licensing or partnering. This allows us to maximise the return on our investment.
We maintain a lean cost base with a small, highly specialised team and use trusted third-party providers to maximise return on investment.